XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUE - Schedule of Total Revenue by Type and by U.S versus Rest of World (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Total revenue $ 213.3 $ 191.9 $ 627.0 $ 556.6
U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 196.0 172.2 574.0 495.4
RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 17.3 19.7 53.0 61.2
Hereditary Cancer        
Disaggregation of Revenue [Line Items]        
Total revenue 90.5 86.5 270.1 238.9
Hereditary Cancer | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 78.4 75.1 235.6 203.6
Hereditary Cancer | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 12.1 11.4 34.5 35.3
Tumor Profiling        
Disaggregation of Revenue [Line Items]        
Total revenue 31.6 30.2 95.1 103.5
Tumor Profiling | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 26.5 22.0 77.1 78.1
Tumor Profiling | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 5.1 8.2 18.0 25.4
Prenatal        
Disaggregation of Revenue [Line Items]        
Total revenue 43.5 39.5 132.2 111.3
Prenatal | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 43.4 39.4 131.7 110.8
Prenatal | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 0.1 0.1 0.5 0.5
Pharmacogenomics        
Disaggregation of Revenue [Line Items]        
Total revenue 47.7 35.7 129.6 102.9
Pharmacogenomics | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 47.7 35.7 129.6 102.9
Pharmacogenomics | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue $ 0.0 $ 0.0 $ 0.0 $ 0.0